Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-Guard in Steroid-Resistant Acute GVHD
NCT02027805Phase 2Completed
- Sponsor
- Xenikos
- Start
- Mar 2014
- Primary completion
- Sep 2016
- Modality
- Monoclonal Antibodies, Immunotoxins
- Countries
- 2
01
Overview
A Phase 2 trial of T-Guard in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Xenikos. Started Mar 2014; status: completed.
02
Drugs
T-Guard
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT02027805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02027805.